Advanced Care for Non-Small Cell Lung Cancer
Battling lung cancer, bladder cancer, or other specific cancers? Tecentriq 1200 mg is designed to support patients with conditions like non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), urothelial carcinoma, or hepatocellular carcinoma, offering targeted immunotherapy to improve treatment outcomes.
How it Supports Your Treatment Plan
This prescription medicine contains Atezolizumab, a monoclonal antibody that works as an immune checkpoint inhibitor. It targets the PD-L1 protein on cancer cells, enabling the immune system to recognize and attack cancer cells more effectively, helping to slow disease progression and improve survival rates.
Recommended Usage
Tecentriq 1200 mg should only be administered under the supervision of a healthcare professional, typically in a clinical setting via intravenous infusion over 60 minutes every 3 weeks. Follow your doctor’s instructions regarding dosage and infusion schedule to ensure safe and effective treatment.
Possible Side Effects to Watch
Tecentriq (atezolizumab), in the 1200 mg dosage, can cause a range of side effects, some mild and others serious. Mild side effects include:
• Fatigue
• Decreased appetite
• Nausea
• Diarrhea
More severe reactions, which may require immediate medical attention, include inflammation of the heart, lungs, liver, kidneys, or nervous system, as well as infusion reactions, and changes in urination or bowel movements.
Get Genuine Tecentriq 1200 mg in Pakistan
For those checking availability and cost, the Tecentriq 1200 mg price in Pakistan is listed on the verified platforms that specialize in secure medication delivery. Choose Jasmeds, a trustworthy online delivery pharmacy that guarantees proper storage, real-time tracking, and responsive customer service to ensure a smooth and trustworthy experience.
Buy Tecentriq 1200 mg online today and skip the hassle of visiting multiple pharmacies, waiting in long queues, or dealing with stock shortages
Reviews
Clear filtersThere are no reviews yet.